Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies

Authors	RADOCHA Jakub MAISNAR Vladimír POUR Luděk ŠPIČKA Ivan MINAŘÍK Jiří SZELIGOVÁ Lenka PAVLÍČEK Petr JUNGOVÁ Alexandra KREJČÍ Marta PIKA Tomáš STRAUB Jan BROŽOVÁ Lucie STEJSKAL Lukáš HEINDORFER Adriana JINDRA Pavel KESSLER Petr MIKULA Peter SYKORA Michal WRÓBEL Marek JARKOVSKÝ Jiří HAJEK Roman
Year of publication	2018
Type	Article in Periodical
Magazine / Source	Cancer Medicine
MU Faculty or unit	Faculty of Medicine
Citation
Doi	http://dx.doi.org/10.1002/cam4.1620
Keywords	Czech Myeloma Group Registry; monoclonal gammopathies; multiple myeloma; overall survival; real-world; risk stratification
Description	This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group (IMWG) and revised International Staging System (R-ISS) indices for risk stratification in patients with multiple myeloma (MM) in clinical practice. Patients were included if they had symptomatic MM, complete data allowing R-ISS and IMWG staging (including cytogenetic information regarding t(4;14), t(14;16), and del(17p)), and key parameters for treatment evaluation. Median overall survival (OS) in included patients (n = 550) was 47.7 (95% CI: 39.5-55.9) and 46.2 (95% CI: 38.9-53.5) months from diagnosis and initiation of first-line therapy, respectively. Patients categorized as higher vs lower risk had reduced survival; median OS from diagnosis was 35.4 (95% CI: 30.5-40.3) vs 58.3 (95% CI: 53.8-62.9) months in high-risk vs other patients (IMWG; P = .001) and 34.1 (95% CI: 30.2-38.0) vs 47.2 (95% CI: 43.4-51.0) months in Stage III vs Stage II patients (R-ISS; P < .001). In conclusion, IMWG and R-ISS risk stratification indices are applicable to patients with MM in a real-world setting.